{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:05:32Z","timestamp":1761609932342,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T00:00:00Z","timestamp":1536537600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s40259-018-0304-3","type":"journal-article","created":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T08:51:08Z","timestamp":1536569468000},"page":"415-423","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Risk of Adverse Drug Events Observed with Baricitinib 2\u00a0mg Versus Baricitinib 4\u00a0mg Once Daily for the Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3269-7530","authenticated-orcid":false,"given":"Feng","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zu-chun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,10]]},"reference":[{"issue":"1","key":"304_CR1","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13075-018-1586-z","volume":"20","author":"C Engdahl","year":"2018","unstructured":"Engdahl C, Bondt A, Harre U, Raufer J, Pfeifle R, Camponeschi A, Wuhrer M, Seeling M, M\u00e5rtensson IL, Nimmerjahn F, Kr\u00f6nke G, Scherer HU, Forsblad-d\u2019Elia H, Schett G. Estrogen induces St6gal1 expression and increases IgG sialylation in mice and patients with\u00a0rheumatoid arthritis: a potential explanation for the increased risk of\u00a0rheumatoid arthritis\u00a0in postmenopausal women. Arthritis Res Ther. 2018;20(1):84.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"304_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41413-018-0016-9","volume":"27","author":"Q Guo","year":"2018","unstructured":"Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res. 2018;27(6):15.","journal-title":"Bone Res"},{"issue":"10","key":"304_CR3","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1177\/0018578717729668","volume":"52","author":"S Turan","year":"2017","unstructured":"Turan S, Walker S. Janus kinase inhibitors\u00a0for the treatment of\u00a0rheumatoid arthritis. Hosp Pharm. 2017;52(10):667\u20138.","journal-title":"Hosp Pharm"},{"issue":"5","key":"304_CR4","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s40259-016-0190-5","volume":"30","author":"S Nakayamada","year":"2016","unstructured":"Nakayamada S, Kubo S, Iwata S, Tanaka Y. Recent\u00a0progress\u00a0in\u00a0JAK inhibitors\u00a0for the\u00a0treatment\u00a0of\u00a0rheumatoid arthritis. BioDrugs. 2016;30(5):407\u201319.","journal-title":"BioDrugs"},{"issue":"7","key":"304_CR5","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s40265-018-0908-4","volume":"78","author":"ZT Al-Salama","year":"2018","unstructured":"Al-Salama ZT, Scott LJ. Baricitinib: a review in\u00a0rheumatoid arthritis. Drugs. 2018;78(7):761\u201372.","journal-title":"Drugs"},{"issue":"6","key":"304_CR6","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s40265-017-0723-3","volume":"77","author":"A Markham","year":"2017","unstructured":"Markham A. Baricitinib: first global approval. Drugs. 2017;77(6):697\u2013704.","journal-title":"Drugs"},{"key":"304_CR7","doi-asserted-by":"crossref","unstructured":"Zamora NV, Tayar J, Lopez-Olivo MA, Christensen R, Suarez-Almazor M. Baricitinib for rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Rheumatol.\u00a02016;68 (suppl 10). https:\/\/acrabstracts.org\/abstract\/baricitinib-for-rheumatoid-arthritis-a-systematic-review-and-meta-analysis\/ . Accessed 22 Aug 2018.","DOI":"10.1002\/14651858.CD013311"},{"key":"304_CR8","unstructured":"FDA briefing document\u2014Arthritis Advisory Committee meeting, 23 April 2018."},{"key":"304_CR9","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/9780470712184.ch8","volume-title":"Assessing risk of bias in included studies. Cochrane handbook for systematic reviews of interventions","author":"JP Higgins","year":"2008","unstructured":"Higgins JP, et al. Assessing risk of bias in included studies. Cochrane handbook for systematic reviews of interventions. New York: Wiley; 2008. p. 187\u2013241."},{"key":"304_CR10","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al. The\u00a0PRISMA\u00a0statement\u00a0for\u00a0reporting\u00a0systematic\u00a0reviews\u00a0and\u00a0meta-analyses\u00a0of\u00a0studies\u00a0that\u00a0evaluate\u00a0healthcare interventions:\u00a0explanation\u00a0and\u00a0elaboration. BMJ. 2009;339:b2700.","journal-title":"BMJ"},{"issue":"1","key":"304_CR11","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","volume":"76","author":"M Dougados","year":"2017","unstructured":"Dougados M, van der Heijde D, Chen YC, Greenwald M, Drescher E, Liu J, Beattie S, Witt S, de la Torre I, Gaich C, Rooney T, Schlichting D, de Bono S, Emery P. Baricitinib\u00a0in\u00a0patients\u00a0with\u00a0inadequate\u00a0response\u00a0or\u00a0intolerance\u00a0to\u00a0conventional\u00a0synthetic DMARDs:\u00a0results\u00a0from the\u00a0RA-BUILD\u00a0study. Ann Rheum Dis. 2017;76(1):88\u201395.","journal-title":"Ann Rheum Dis."},{"issue":"13","key":"304_CR12","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","volume":"374","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, Beattie SD, Koch AE, Cardillo TE, Rooney TP, Macias WL, de Bono S, Schlichting DE, Smolen JS. Baricitinib\u00a0in\u00a0patients\u00a0with\u00a0refractory\u00a0rheumatoid arthritis. N Engl J Med. 2016;374(13):1243\u201352.","journal-title":"N Engl J Med."},{"issue":"1","key":"304_CR13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3899\/jrheum.161161","volume":"45","author":"EC Keystone","year":"2018","unstructured":"Keystone EC, Genovese MC, Schlichting DE, de la Torre I, Beattie SD, Rooney TP, Taylor PC. Safety\u00a0and\u00a0efficacy\u00a0of\u00a0baricitinib\u00a0through\u00a0128\u00a0weeks\u00a0in an\u00a0open-label, longterm extension study in patients with rheumatoid arthritis. J Rheumatol. 2018;45(1):14\u201321.","journal-title":"J Rheumatol."},{"issue":"3","key":"304_CR14","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3899\/jrheum.150613","volume":"43","author":"Y Tanaka","year":"2016","unstructured":"Tanaka Y, Emoto K, Cai Z, Aoki T, Schlichting D, Rooney T, Macias W. Efficacy\u00a0and\u00a0safety\u00a0of\u00a0baricitinib\u00a0in\u00a0Japanese\u00a0patients\u00a0with\u00a0active\u00a0rheumatoid\u00a0arthritis receiving background methotrexate therapy: a 12-week, double-blind. Randomized placebo-controlled study. J Rheumatol. 2016;43(3):504\u201311.","journal-title":"J Rheumatol."},{"issue":"2","key":"304_CR15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","volume":"74","author":"EC Keystone","year":"2015","unstructured":"Keystone EC, Taylor PC, Drescher E, Schlichting DE, Beattie SD, Berclaz PY, Lee CH, Fidelus-Gort RK, Luchi ME, Rooney TP, Macias WL, Genovese MC. Safety\u00a0and\u00a0efficacy\u00a0of\u00a0baricitinib\u00a0at\u00a024 weeks\u00a0in\u00a0patients\u00a0with\u00a0rheumatoid\u00a0arthritis\u00a0who\u00a0have had an\u00a0inadequate\u00a0response\u00a0to\u00a0methotrexate. Ann Rheum Dis. 2015;74(2):333\u201340.","journal-title":"Ann Rheum Dis."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-018-0304-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-018-0304-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-018-0304-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:58:03Z","timestamp":1661993883000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-018-0304-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,10]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["304"],"URL":"https:\/\/doi.org\/10.1007\/s40259-018-0304-3","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"type":"print","value":"1173-8804"},{"type":"electronic","value":"1179-190X"}],"subject":[],"published":{"date-parts":[[2018,9,10]]},"assertion":[{"value":"10 September 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Ethical approval was not applicable for this systematic review and meta-analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Feng Huang and Zu-chun Luo declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No external funding was used in the preparation of this manuscript. This research was supported by the National Natural Science Foundation of China (nos. 81560046, 81760057) and Guangxi Natural Science Foundation (no. 2016GXNSFAA380002).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}}]}}